Separation of Monosaccharides Hydrolyzed from Glycoproteins Without the Need for Derivatization

Total Page:16

File Type:pdf, Size:1020Kb

Separation of Monosaccharides Hydrolyzed from Glycoproteins Without the Need for Derivatization Anal Bioanal Chem DOI 10.1007/s00216-015-8717-z RESEARCH PAPER Separation of monosaccharides hydrolyzed from glycoproteins without the need for derivatization Mark S. Lowenthal1 & Eric L. Kilpatrick1 & Karen W. Phinney1 Received: 20 January 2015 /Revised: 27 March 2015 /Accepted: 16 April 2015 # Springer-Verlag Berlin Heidelberg (outside the USA) 2015 Abstract Chromatographic separation of monosaccharides Introduction hydrolyzed from glycoconjugates or complex, aggregate bio- materials, can be achieved by classic analytical methods with- Characterization of carbohydrates and glycans in biological out a need for derivatizing the monosaccharide subunits. A systems is of critical interest in several diverse areas including simple and sensitive method is presented for characterizing therapeutics development [1, 2], disease diagnostics (cancer, underivatized monosaccharides following hydrolysis from heart disease, diabetes, and numerous others) [3–5], and elu- N- and O-linked glycoproteins using high-performance liquid cidation of biological processes [6–9] (cellular metabolism, chromatography separation with mass spectrometry detection biosynthesis, and development). Additionally, greater under- (LC-MS). This method is adaptable for characterizing any- standing of protein folding [10, 11], immunity, energy storage, thing from purified glycoproteins to mixtures of glycoforms, and other areas are dependent on knowledge of glycan com- for relative or absolute quantification applications, and even position. Due to the sheer numbers of possible forms, along for the analysis of complex biomaterials. Use of an amide with their chemical similarity and structural complexity, car- stationary phase with HILIC chromatography is demonstrated bohydrates are among the most difficult classes of biomole- to retain the highly polar, underivatized monosaccharides and cules to characterize and/or quantify whether they exist as to resolve stereoisomers and potentially interfering contami- purely saccharide forms (mono-, oligo-, or poly-saccharide), nants. This work illustrates an original approach for character- or bound to other types of biomolecules forming ization of N- and O-linked glycoprotein standards, mixtures, glycoconjugates (glycoproteins, glycolipids, or proteogly- and for complex biological materials such as a total yeast cans). While complex in the aggregate, glycoconjugates are extract. principally composed of a small class of similar, yet measur- able, subunits of monosaccharides. Mammalian glycosyla- tions are made up of a limited number of monosaccharide Keywords Bioanalytical methods . HPLC . Mass forms – principally galactose, glucose, mannose, fructose, fu- spectrometry / ICP-MS . Separations/Instrumentation cose, N-acetyl glucosamine (GlcNAc), N-acetyl galactos- amine (GalNAc), N-acetyl neuraminic acid (NANA), and rarely, N-glycolyl neuraminic acid (NGNA). Other minor components are seldom included such as xylose, iduronic ac- id, others. Each of these monomeric forms can be uniquely Electronic supplementary material The online version of this article (doi:10.1007/s00216-015-8717-z) contains supplementary material, detected in a mass spectrometer as an underivatized com- which is available to authorized users. pound based on a fragmentation pattern alone, or in cases of stereoisomers, with additional chromatographic retention * Mark S. Lowenthal information. mark.lowenthal@nist.gov Monosaccharide characterization offers valuable compli- mentary data to the analysis of intact glycans or glycoprotein 1 Biomolecular Measurement Division, National Institute of Standards characterization. Total monosaccharide characterization is and Technology, Gaithersburg, MD 20899, USA possible for simple or complex mixtures, and can take account M.S. Lowenthal et al. of monosaccharides originating from non-targeted proteins or an approach for monosaccharide characterization that isn’t unexpected impurities. The characterization of biosimilars – currently available. protein therapeutics sharing similar function but with intrinsic structural variability – relies on data obtained at the glycan level, a technically difficult task often hampered by the lack Experimental of commercially available homogenous glycoprotein stan- dards and by the complexity of known and potentially un- Disclaimer Certain commercial equipment, instruments, and known glycoforms. Furthermore, biases of omission are com- materials are identified in this paper to adequately specify the mon in glycan profiling. For instance, contributions from experimental procedure. Such identification does not imply host-cell proteins, excipients, or glycation to the overall car- recommendation or endorsement by NIST nor does it imply bohydrate composition of a biosimilar product are often that the equipment, instruments, or materials are necessarily overlooked when measured at the glycan level, but are intrin- the best available for the purpose. sically considered by monosaccharide measurements. The qualitative approach presented here using mass spectrometry detection offers the potential to perform quantitative measure- Materials ments using isotope dilution (ID) techniques, which is not currently possible using HPAEC-PAD or other detection tech- All chemicals and solvents were purchased through Sigma niques. Monosaccharide internal standards are available com- (St. Louis, MO) unless otherwise noted below. Isotope- mercially, and may be applied generally to IS-MS measure- labeled monosaccharide standards were purchased through ments. Monosaccharide characterization is therefore sug- Omicron Biochemicals (South Bend, IN). Unlabeled mono- gested to be a valuable complementary tool for assessing the saccharide standards were purchased through Sigma (Aldrich degree of biosimilarity. and Fluka). Casein from bovine milk (C7078), fetuin from Although there are previous literature reports that describe fetal calf serum (F2379), and yeast extract (Y4250) were also acid hydrolysis of glycoproteins into their constituent mono- purchased through Sigma. saccharide units with subsequent analysis using LC-MS [12–17] or capillary electrophoresis [18], each of these studies Sample preparation requires derivitization of monosaccharides for detection, like- ly incorporating measurement bias in proportion to the label- Stable-isotope (13C) labeled analogs of each monosaccharide ing inefficiency. The current industry standard for analysis of were purchased from commercial sources and pre-spiked at non-derivatized, hydrolyzed sugars – anion exchange chroma- the earliest possible step in the sample preparation (se tography with pulsed amperometric detection [19](HPAEC- Electronic Supplementary Material (ESM) Table SI). In the PAD) – is capable of chromatographic resolution of monosac- case for a total yeast extract sample, a glycoprotein extraction charides and can be a very sensitive detection technique, but is step with methanol/chloroform (MeOH/CHCl3) was neces- inherently incompatible with direct mass spectrometry detec- sary to first precipitate the protein sample prior to spiking tion, and therefore incompatible with isotope dilution tech- the labeled analogs. Protein precipitation was performed with- niques. In contrast, the work described here presents a novel in a 400-μL glass autosampler vial insert (Agilent 5181-3377) method focusing on chromatographic resolution and mass that was then used for the acid hydrolysis, reducing protein spectral detection of monosaccharides without modification. loss. In all other cases, pre-spiked samples were dried in a One certain way to improve monosaccharide measurements is speed vac (ThermoSavant SPD1010) and subjected separately through simplifying the sample preparation. This effort reports to each of three unique acid hydrolyses. Hydrolysis was per- a workflow for releasing monosaccharides from intact glyco- formed in a similar manner to previously reported studies by proteins and characterizing them by multiple reaction moni- Mechref’sgroup[16, 17]. In all cases, gas-phase hydrolysis toring (MRM) using liquid chromatography-tandem mass was achieved within a capped glass vial housing the glass spectrometry (LC-MS/MS) techniques. An amide stationary autosampler insert. Figure 1 provides a schematic of the sam- chemistry was used within a normal phase (HILIC) environ- ple preparation procedure for each monosaccharide class. ment to resolve ten underivatized monosaccharides prior to Briefly, glycoproteins were denatured, and neutral sugars negative polarity electrospray ionization, and detection in a (mannose, galactose, glucose, fructose, and fucose) or amine triple quadrupole mass spectrometer. This analytical approach sugars (GlcNAc and GalNAc) were liberated from their gly- is demonstrated in principle for N-linked glycoproteins (im- coprotein precursors using 2 mol/L trifluoroacetic acid (TFA, munoglobulins, RNAse B), O-linked glycoproteins (casein, Fluka 91699) or 4 mol/L hydrochloric acid (HCl, Fluka fetuin), and a complex yeast extract. The combination of sim- 84410), respectively, at 100 °C for 4 h. Sialic acids (NANA, plified sample preparation presented here with chromato- NGNA), being terminal subunits and less chemically stable, graphic separation and mass spectrometric detection provides were hydrolyzed under milder conditions (0.1 mol/L TFA for Monosaccharide characterization without derivatization Fig. 1 Schematic for the hydrolysis and preparation of each monosaccharide class (neutrals, amine sugars, sialic acids) prior to LC-MS analysis 2 h at
Recommended publications
  • Metabolism of Monosaccharides and Disaccharides Glucose Is the Most Common Monosaccharide Consumed by Humans
    Metabolism of Monosaccharides and disaccharides Glucose is the most common monosaccharide consumed by humans. Two other monosaccharides that occur in significant amounts in the diet are fructose and galactose. Galactose is an important component of cell structural carbohydrates. Catabolism of fructose and galactose are essential pathways of energy metabolism in the body (both illustrated with blue in the adjacent diagram). About 15-20% of calories in the diet are supplied by fructose (55 g/day). The major source of fructose is the disaccharide sucrose. Entry of fructose is not dependent on insulin. Galactose is an important component Of cell structural carbohydrates. Fructose needs to be phosphorylated to enter the pathway either by hexokinase or fructokinase. Hexokinase has low affinity towards fructose (high Km) therefore unless high concentrations of fructose exist very little fructose will be converted to Fructose 6-P. Fructokinase provides the main mechanism of phosphorylation to fructose 1-P, Fructose 1-P does not convert to Fructose 1,6 bisphosphate but is metabolized to Glyceraldehyde and DHAP by aldolase B. DHAP can enter glycolysis or gluconeogenesis while Glyceraldehyde can be metabolized by a number of pathways. The rate of fructose metabolism is more rapid than that of glucose because trioses formed from fructose 1-phosphate bypass PFK1, the rate limiting step in glycolisis. What disorders are associated with fructose metabolism? Where? First lets summarize the various routes of Fructose metabolism in the diagram. Disorders of fructose metabolism can result from excessive fructose consumption. An increase in fructose 1-P due to rapid phosphorylation. This accumulation leads to sequestering of phosphate (A & B).
    [Show full text]
  • Electronic Supplementary Information
    Electronic Supplementary Material (ESI) for Chemical Science. This journal is © The Royal Society of Chemistry 2019 Electronic Supplementary Information Poly(ionic liquid)s as a Distinct Receptor Material to Create Highly- Integrated Sensing Platform for Efficiently Identifying a Myriad of Saccharides Wanlin Zhang, Yao Li, Yun Liang, Ning Gao, Chengcheng Liu, Shiqiang Wang, Xianpeng Yin, and Guangtao Li* *Corresponding authors: Guangtao Li (lgt@mail.tsinghua.edu.cn) S1 Contents 1. Experimental Section (Page S4-S6) Materials and Characterization (Page S4) Experimental Details (Page S4-S6) 2. Figures and Tables (Page S7-S40) Fig. S1 SEM image of silica colloidal crystal spheres and PIL inverse opal spheres. (Page S7) Fig. S2 Adsorption isotherm of PIL inverse opal. (Page S7) Fig. S3 Dynamic mechanical analysis and thermal gravimetric analysis of PIL materials. (Page S7) Fig. S4 Chemical structures of 23 saccharides. (Page S8) Fig. S5 The counteranion exchange of PIL photonic spheres from Br- to DCA. (Page S9) Fig. S6 Reflection and emission spectra of spheres for saccharides. (Page S9) Table S1 The jack-knifed classification on single-sphere array for 23 saccharides. (Page S10) Fig. S7 Lower detection concentration at 10 mM of the single-sphere array. (Page S11) Fig. S8 Lower detection concentration at 1 mM of the single-sphere array. (Page S12) Fig. S9 PIL sphere exhibiting great pH robustness within the biological pH range. (Page S12) Fig. S10 Exploring the tolerance of PIL spheres to different conditions. (Page S13) Fig. S11 Exploring the reusability of PIL spheres. (Page S14) Fig. S12 Responses of spheres to sugar alcohols. (Page S15) Fig.
    [Show full text]
  • Pharmaceutical Compositions of Rifaximin Pharmazeutische Rifaximin-Zusammensetzungen Compositions Pharmaceutiques De Rifaximine
    (19) TZZ Z__ T (11) EP 2 011 486 B2 (12) NEW EUROPEAN PATENT SPECIFICATION After opposition procedure (45) Date of publication and mention (51) Int Cl.: of the opposition decision: A61K 9/20 (2006.01) A61K 31/44 (2006.01) 12.08.2015 Bulletin 2015/33 (45) Mention of the grant of the patent: 23.05.2012 Bulletin 2012/21 (21) Application number: 08252198.0 (22) Date of filing: 26.06.2008 (54) Pharmaceutical compositions of rifaximin Pharmazeutische Rifaximin-Zusammensetzungen Compositions pharmaceutiques de rifaximine (84) Designated Contracting States: (56) References cited: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR EP-A1- 0 616 808 EP-B1- 1 763 339 HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT WO-A-2006/094737 WO-A2-2006/039022 RO SE SI SK TR US-A- 6 140 355 US-A1- 2005 101 598 (30) Priority: 06.07.2007 IN KO09682007 • DUPONT ET AL: "Treatment of Travelers’ 23.06.2008 EP 08252158 Diarrhea: Randomized Trial Comparing Rifaximin, Rifaximin Plus Loperamide, and (43) Date of publication of application: Loperamide Alone" CLINICAL 07.01.2009 Bulletin 2009/02 GASTROENTEROLOGY AND HEPATOLOGY, AMERICAN GASTROENTEROLOGICAL (60) Divisional application: ASSOCIATION, US, vol. 5, no. 4, 17 April 2007 11176043.5 / 2 420 226 (2007-04-17), pages 451-456, XP022029177 ISSN: 14186563.4 / 2 837 378 1542-3565 • ARYA ET AL: "Rifaximin-the promising anti- (73) Proprietor: Lupin Ltd. microbial for enteric infections" JOURNAL OF Mumbai, Maharashtra 400 098 (IN) INFECTION, ACADEMIC PRESS, LONDON, GB, vol.
    [Show full text]
  • Conversion of Exhausted Sugar Beet Pulp Into Fermentable Sugars from a Biorefinery Approach
    foods Article Conversion of Exhausted Sugar Beet Pulp into Fermentable Sugars from a Biorefinery Approach Cristina Marzo , Ana Belén Díaz * , Ildefonso Caro and Ana Blandino Department of Chemical Engineering and Food Technology, Faculty of Sciences, IVAGRO, University of Cádiz, Campus Universitario de Puerto Real, 11510 Puerto Real, Spain; cristina.marzo@gm.uca.es (C.M.); ildefonso.caro@uca.es (I.C.); ana.blandino@uca.es (A.B.) * Correspondence: anabelen.diaz@uca.es Received: 29 August 2020; Accepted: 21 September 2020; Published: 24 September 2020 Abstract: In this study, the production of a hydrolysate rich in fermentable sugars, which could be used as a generic microbial culture medium, was carried out by using exhausted sugar beet pulp pellets (ESBPPs) as raw material. For this purpose, the hydrolysis was performed through the direct addition of the fermented ESBPPs obtained by fungal solid-state fermentation (SSF) as an enzyme source. By directly using this fermented solid, the stages for enzyme extraction and purification were avoided. The effects of temperature, fermented to fresh solid ratio, supplementation of fermented ESBPP with commercial cellulase, and the use of high-solid fed-batch enzymatic hydrolysis were studied to obtain the maximum reducing sugar (RS) concentration and productivity. The highest RS concentration and productivity, 127.3 g L 1 and 24.3 g L 1 h 1 respectively, were obtained at 50 C · − · − · − ◦ and with an initial supplementation of 2.17 U of Celluclast® per gram of dried solid in fed-batch mode. This process was carried out with a liquid to solid ratio of 4.3 mL g 1 solid, by adding 15 g · − of fermented solid and 13.75 g of fresh solid at the beginning of the hydrolysis, and then the same amount of fresh solid 3 times every 2.5 h.
    [Show full text]
  • A Review of Physiological Effects of Soluble and Insoluble Dietary Fibers
    ition & F tr oo u d N f S o c l i e a n n c r e u s o J Journal of Nutrition & Food Sciences Perry and Ying, J Nutr Food Sci 2016, 6:2 ISSN: 2155-9600 DOI: 10.4172/2155-9600.1000476 Review Article Open Access A Review of Physiological Effects of Soluble and Insoluble Dietary Fibers Perry JR and Ying W* College of Agriculture, Human, and Natural Sciences, 13500 John A Merritt, Tennessee State University, Nashville, TN, USA *Corresponding author: Ying W, College of Agriculture, Human, and Natural Sciences, 13500 John A Merritt, Tennessee State University, Nashville, TN, United States, Tel: 615-963-6006; E-mail: ywu@TNstate.edu Rec date: Feb 18, 2016; Acc date: Mar 03, 2016; Pub date: Mar 14, 2016 Copyright: © 2016 Perry JR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract This paper seeks to characterize the effects of Total Dietary Fibers (TDFs), Soluble Dietary Fibers (SDFs), and Insoluble Dietary Fibers (IDFs) with regard to the rates of digestion, enzymatic activity, the metabolic syndrome, diabetes and glucose absorption, glycemic index, and weight gain. This review intends to narrow pertinent data from the vast body of research, including both in vivo and in vitro experiments. SDF and IDF share a number of the theorized beneficial properties in the diet including weight loss, increased satiety, effects on inflammatory markers, and intestinal microbiota.
    [Show full text]
  • GRAS Notice 735 for 2'-Fucosyllactose
    GRAS Notice (GRN) No. 735 https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/default.htm GRAS Associates, LLC 27499 Riverview Center Blvd. Bonita Springs, FL 34134 GRifS T: 239.444.1724 J F: 239.444.1723 ASSOCIATES, LLC www.gras-associates.com September 29, 2017 GR N 0rf'rrl 3 5 Food and Drug Administration Center for Food Safety & Applied Nutrition Office of Food Additive Safety (HFS-255) 5001 Campus Drive College Park, MD 20740-3835 Attention: Dr. Paulette Gaynor Re: GRAS Notification-2'-Fucosyllactose Dear Dr. Gaynor: GRAS Associates, LLC, acting as the agent for Glycosyn, LLC (Woburn, MA) and FrieslandCampina Domo B.V. (The Netherlands) is submitting for FDA review Form 3667 and the enclosed CD, free of viruses, containing a GRAS notification for 2'-Fucosyllactose produced by microbial fermentation. Along with Glycosyn and FrieslandCampina's determination of safety, an Expert Panel of qualified persons was assembled to assess the composite safety information of the subject substance with the intended use as an ingredient in infant formulas, conventional foods, and medical foods at levels ranging from 0.24 to 4.0 grams 2'-fucosyllactose per serving. The attached documentation contains the specific information that addresses the safe human food uses for the subject notified substance as discussed in the GRAS guidance document. If additional information or clarification is needed as you and your colleagues proceed with the review, please feel free to contact me via telephone or email. We look forward to your feedback. Sincerely, (b) (6) Katrina V. Emmel, Ph.D. Senior Scientist/Associate GRAS Associates, LLC 27499 Riverview Center Blvd., Suite 212 Bonita Springs, FL 34134 OCT 2 2017 951-496-4178 OFFICE OF emmel@gras-associates.com FOOD ADDITIVE SAFETY Enclosure: GRAS Notification for Glycosyn and FrieslandCampina -2'-Fucosyllactose ., Form Approved: OMB No.
    [Show full text]
  • Sweeteners Georgia Jones, Extension Food Specialist
    ® ® KFSBOPFQVLCB?O>PH>¨ FK@LIKUQBKPFLK KPQFQRQBLCDOF@RIQROB>KA>QRO>IBPLRO@BP KLTELT KLTKLT G1458 (Revised May 2010) Sweeteners Georgia Jones, Extension Food Specialist Consumers have a choice of sweeteners, and this NebGuide helps them make the right choice. Sweeteners of one kind or another have been found in human diets since prehistoric times and are types of carbohy- drates. The role they play in the diet is constantly debated. Consumers satisfy their “sweet tooth” with a variety of sweeteners and use them in foods for several reasons other than sweetness. For example, sugar is used as a preservative in jams and jellies, it provides body and texture in ice cream and baked goods, and it aids in fermentation in breads and pickles. Sweeteners can be nutritive or non-nutritive. Nutritive sweeteners are those that provide calories or energy — about Sweeteners can be used not only in beverages like coffee, but in baking and as an ingredient in dry foods. four calories per gram or about 17 calories per tablespoon — even though they lack other nutrients essential for growth and health maintenance. Nutritive sweeteners include sucrose, high repair body tissue. When a diet lacks carbohydrates, protein fructose corn syrup, corn syrup, honey, fructose, molasses, and is used for energy. sugar alcohols such as sorbitol and xytilo. Non-nutritive sweet- Carbohydrates are found in almost all plant foods and one eners do not provide calories and are sometimes referred to as animal source — milk. The simpler forms of carbohydrates artificial sweeteners, and non-nutritive in this publication. are called sugars, and the more complex forms are either In fact, sweeteners may have a variety of terms — sugar- starches or dietary fibers.Table I illustrates the classification free, sugar alcohols, sucrose, corn sweeteners, etc.
    [Show full text]
  • Sia: the Sugar Code of Life
    Journal of General Surgery Open Access Full Text Article Research Article Sia: The Sugar Code of Life This article was published in the following Scient Open Access Journal: Journal of General Surgery Received November 05, 2017; Accepted November 27, 2017; Published December 04, 2017 Robert Skopec* Abstract Analyst-researcher, Dubnik, Slovakia, Europe Our cells are coated with sugar, and when it comes to cancer, that’s anything but sweet. In a recent talk at TEDxStanford, chemist Carolyn Bertozzi explained why. She studies sialic acid, a sugar that seems to deceive the immune system, allowing cancer cells to evade the body’s defenses. This work focuses on the complex, sugary structures surrounding human cells. That foliage-like coating, it turns out, can tell us a lot of our body – it even reveals a patient’s blood type. Sugar and carbohydrates are dangerous supporters of different types of cancer. Introduction As it can be seen from the information of the American Chemical Society (ACS), ideally, the immune system can figure out which cells are bad, attack them and protect the body from disease. In the case of cancer cells, though, a special sugary coating tricks the immune system into ignoring them. The sialic acid, a sugar that’s denser in cancer cells than in other cells. It seems deceive the immune system, allowing the cancer cells to evade the body’s defenses. Unnoticed and unchallenged, cancer cells are free to divideMonosaccharides and run wild inside - Sialic the acid/N-acetylneuraminicbody [1,2]. acid N-acetylneuraminic acid, also known as Sialic acid, is a key component of important amino sugars that mediate cellular communication.
    [Show full text]
  • Fructose and Mannose in Inborn Errors of Metabolism and Cancer
    H OH metabolites OH Review Fructose and Mannose in Inborn Errors of Metabolism and Cancer Elizabeth L. Lieu †, Neil Kelekar †, Pratibha Bhalla † and Jiyeon Kim * Department of Biochemistry and Molecular Genetics, University of Illinois, Chicago, IL 60607, USA; elieu3@uic.edu (E.L.L.); nkelek2@illinois.edu (N.K.); pbhall4@uic.edu (P.B.) * Correspondence: jiyeonk@uic.edu † These authors contributed equally to this work. Abstract: History suggests that tasteful properties of sugar have been domesticated as far back as 8000 BCE. With origins in New Guinea, the cultivation of sugar quickly spread over centuries of conquest and trade. The product, which quickly integrated into common foods and onto kitchen tables, is sucrose, which is made up of glucose and fructose dimers. While sugar is commonly associated with flavor, there is a myriad of biochemical properties that explain how sugars as biological molecules function in physiological contexts. Substantial research and reviews have been done on the role of glucose in disease. This review aims to describe the role of its isomers, fructose and mannose, in the context of inborn errors of metabolism and other metabolic diseases, such as cancer. While structurally similar, fructose and mannose give rise to very differing biochemical properties and understanding these differences will guide the development of more effective therapies for metabolic disease. We will discuss pathophysiology linked to perturbations in fructose and mannose metabolism, diagnostic tools, and treatment options of the diseases. Keywords: fructose and mannose; inborn errors of metabolism; cancer Citation: Lieu, E.L.; Kelekar, N.; Bhalla, P.; Kim, J. Fructose and Mannose in Inborn Errors of Metabolism and Cancer.
    [Show full text]
  • Enzymatic Synthesis of L-Fucose from L-Fuculose Using a Fucose Isomerase
    Kim et al. Biotechnol Biofuels (2019) 12:282 https://doi.org/10.1186/s13068-019-1619-0 Biotechnology for Biofuels RESEARCH Open Access Enzymatic synthesis of L-fucose from L-fuculose using a fucose isomerase from Raoultella sp. and the biochemical and structural analyses of the enzyme In Jung Kim1†, Do Hyoung Kim1†, Ki Hyun Nam1,2 and Kyoung Heon Kim1* Abstract Background: L-Fucose is a rare sugar with potential uses in the pharmaceutical, cosmetic, and food industries. The enzymatic approach using L-fucose isomerase, which interconverts L-fucose and L-fuculose, can be an efcient way of producing L-fucose for industrial applications. Here, we performed biochemical and structural analyses of L-fucose isomerase identifed from a novel species of Raoultella (RdFucI). Results: RdFucI exhibited higher enzymatic activity for L-fuculose than for L-fucose, and the rate for the reverse reaction of converting L-fuculose to L-fucose was higher than that for the forward reaction of converting L-fucose to L-fuculose. In the equilibrium mixture, a much higher proportion of L-fucose (~ ninefold) was achieved at 30 °C and pH 7, indicating that the enzyme-catalyzed reaction favors the formation of L-fucose from L-fuculose. When biochemical analysis was conducted using L-fuculose as the substrate, the optimal conditions for RdFucI activity were determined to be 40 °C and pH 10. However, the equilibrium composition was not afected by reaction temperature in the range 2 of 30 to 50 °C. Furthermore, RdFucI was found to be a metalloenzyme requiring Mn + as a cofactor. The comparative crystal structural analysis of RdFucI revealed the distinct conformation of α7–α8 loop of RdFucI.
    [Show full text]
  • Hydrocolloids Structure and Properties the Building Blocks for Structure Timothy J
    Hydrocolloids Structure and Properties The building blocks for structure Timothy J. Foster 18 month Meeting, Unilever Vlaardingen, March 29‐31, 2010 Manufactured Materials Foams Emulsions Natural Materials This shows a layer of onion (Allium) cells. Targeting Hydrocolloids For Specific Applications: Approach Material Ingredient Properties Microstructure Oral Process Response Packaging Distribution Storage Process Controlled oral response Process (mouth/gut) Controlling Structure (taste, flavour, texture) CONSTRUCTION DECONSTRUCTION Designed texture/ Ingredient In body functionality Ingredient appearance/ (enzymes) behaviour Interaction with body mucins Reconstruction (associative and new phase separation) Microstructure changes as a Impact on / of starting function of enzyme action materials / structures Re-assembly of structures as a function of digestion breakdown products and body secretions (micelle formation, delivery vehicles) Single Biopolymer systems Hydrocolloid Structure/ Function Need: - define biopolymer primary structure - understand the nature of the interaction / rates - understand the solvent effects - measure material properties - test influence of primary structure variation and changes in environmental conditions on mechanical properties. Hydrocolloid Materials & Function Gelling Thickening Emulsification Pectin Pectin • Gelatin Alginate Alginate • Milk proteins Starch Starch • Egg proteins Agar LBG Carrageenan • Soya proteins Guar gum Gellan • Pea proteins Gelatin Xanthan • Gum Arabic Milk proteins Egg proteins Hydrocolloid
    [Show full text]
  • Pharmaceutical Compositions for Gastrointestinal Drug Delivery
    (19) TZZ Z¥_T (11) EP 2 942 053 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 11.11.2015 Bulletin 2015/46 A61K 9/16 (2006.01) A61K 9/20 (2006.01) A61K 31/437 (2006.01) A61K 31/606 (2006.01) (2006.01) (2006.01) (21) Application number: 15156572.8 A61K 31/635 A61K 38/14 A61K 31/655 (2006.01) A61K 9/00 (2006.01) (2006.01) (22) Date of filing: 26.06.2008 A61K 9/24 (84) Designated Contracting States: • Kulkarni, Rajesh AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 411 042 Pune (IN) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT • Kulkarni, Shirishkumar RO SE SI SK TR 411 042 Pune (IN) (30) Priority: 06.07.2007 IN KO09692007 (74) Representative: Hoffmann Eitle 24.06.2008 EP 08252164 Patent- und Rechtsanwälte PartmbB Arabellastraße 30 (62) Document number(s) of the earlier application(s) in 81925 München (DE) accordance with Art. 76 EPC: 08252197.2 / 2 011 487 Remarks: •This application was filed on 25-02-2015 as a (71) Applicant: Lupin Limited divisional application to the application mentioned Mumbai, Maharashtra 400 098 (IN) under INID code 62. •Claims filed after the date of filing of the application (72) Inventors: (Rule 68(4) EPC). • Jahagirdar, Harshal Anil 411 042 Pune (IN) (54) Pharmaceutical compositions for gastrointestinal drug delivery (57) A pharmaceutical composition, which compris- increase the residence time of the said pharmaceutical es a therapeutically effective amount of active principle composition and/or active principle (s) in the gastrointes- (s) or a pharmaceutically acceptable salt or enantiomer tinal tract.
    [Show full text]